# Erasca (ERAS) — Earnings

ERAS · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/eras/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.12 |
| EPS estimate | −$0.12 |
| EPS surprise | −3.90% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $0.00 |
| Reported | Aug 12, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1761918/000119312525178996/eras-20250630.htm) |

Erasca's most recent quarter in the table is Q2 2025, reported August 12, 2025. The company posted a loss of $0.12 per share, the same as the $0.12 loss expected in rounded terms, and the source records a 3.90% miss. No revenue or revenue estimate is given for any quarter. The loss was narrower than the $0.29 per share lost in Q2 2024.

Every quarter in the table, back to Q2 2021, is a loss, but the losses have narrowed over time. Annual losses were $1.96 per share in 2022, $0.83 in 2023 and $0.74 in 2024. The largest quarterly losses were Q2 2021 at $1.20 and Q4 2022 at $1.06. The four quarters from Q3 2024 to Q2 2025 were all between $0.11 and $0.12. Erasca beat the EPS estimate in 11 of 17 quarters and missed in 6, with the widest miss in Q4 2022 at 166.26%.

The table has no results after Q2 2025. In earlier years, Q3 results came between November 9 and November 12, and full-year results in late March. Newer quarters will show whether the narrower losses of 2024 and early 2025 held.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 12, 2025 | −$0.12 | −$0.12 | -3.90% | — | — |
| Q1 2025 | May 13, 2025 | −$0.12 | −$0.11 | 11.58% | — | — |
| Q4 2024 | Mar 20, 2025 | −$0.12 | −$0.11 | 11.79% | — | — |
| Q3 2024 | Nov 12, 2024 | −$0.17 | −$0.11 | 34.17% | — | — |
| Q2 2024 | Aug 12, 2024 | −$0.18 | −$0.29 | -58.47% | — | — |
| Q1 2024 | May 8, 2024 | −$0.20 | −$0.23 | -14.09% | — | — |
| Q4 2023 | Mar 27, 2024 | −$0.23 | −$0.20 | 11.74% | — | — |
| Q3 2023 | Nov 9, 2023 | −$0.23 | −$0.20 | 13.01% | — | — |
| Q2 2023 | Aug 10, 2023 | −$0.25 | −$0.21 | 16.57% | — | — |
| Q1 2023 | May 15, 2023 | −$0.33 | −$0.22 | 32.39% | — | — |
| Q4 2022 | Mar 23, 2023 | −$0.40 | −$1.06 | -166.26% | — | — |
| Q3 2022 | Nov 9, 2022 | −$0.31 | −$0.29 | 6.45% | — | — |
| Q2 2022 | Aug 11, 2022 | −$0.33 | −$0.30 | 9.64% | — | — |
| Q1 2022 | May 12, 2022 | −$0.29 | −$0.31 | -5.44% | — | — |
| Q4 2021 | Mar 24, 2022 | −$0.36 | −$0.26 | 28.06% | — | — |
| Q3 2021 | Nov 10, 2021 | −$0.51 | −$0.46 | 10.10% | — | — |
| Q2 2021 | Aug 26, 2021 | −$0.71 | −$1.20 | -69.01% | — | — |

## Frequently Asked Questions

### When did Erasca (ERAS) last report earnings?

Erasca last reported on Aug 12, 2025, covering fiscal Q2 2025.

### Did ERAS beat earnings estimates?

No. Erasca reported EPS of −$0.12 for Q2 2025 against a −$0.12 estimate — a 3.90% miss.

## Similar Stocks

- [RVMD](https://www.lighthorse.io/tickers/rvmd) — Revolution Medicines, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).